Abstract:Background:Particulate matter (PM) exposure is related to mitochondria dysfunction and airway inflammation. Antioxidant drug edaravone (EDA) is reported to improve the occurrence and development of oxidative stress-related diseases. At present, there is no data on whether EDA can alleviate lung inflammation caused by PM.Methods:The anti-inflammatory effects of EDA were investigated in urban PM-induced human bronchial epithelial cells (HBECs) and C57/BL6J mouse models. In vitro, its effects on the production of intracellular reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and inflammatory cytokines were assessed by DCFH-DA staining, JC-1 assay, and real-time PCR, respectively. In vivo, the oxidant stress in lung tissues was assessed by dihydroethidium (DHE) staining and malondialdehyde (MDA) activity, and inflammatory cytokines in bronchoalveolar lavage fluid (BALF) were assessed by ELISA, respectively. Furthermore, the potential signaling pathways were studied by siRNA transfection and western blot.Results:PM increased the expression of inflammatory cytokines and protein, including IL-6, IL-1α, IL-1β, and COX-2, while these alternations were significantly alleviated following EDA treatment in a dose-dependent manner. EDA treatment also alleviated the inflammatory responses in lung tissues of PM-exposed mice. We further showed mitochondrial dysfunction in PM-exposed HBECs and mice, which were reversed by EDA treatment. Moreover, the phosphorylation of NF-κB p65 in PM-exposed HBECs and mice was weakened by EDA. Transfection with NF-κB p65 siRNA further inhibited PM-induced inflammation in HBECs.Conclusion:We demonstrated that EDA treatment had a protective role in PM-induced lung inflammation through maintaining mitochondrial balance and regulating the ROS-NF-κB p65 signaling pathway. This provided a new therapeutic method for PM-induced lung inflammation in the future.

[Edaravone Has a Protective Role in a Mouse Model of Pulmonary Oxygen Toxicity].

Compound Edaravone Alleviates Lipopolysaccharide (Lps)-Induced Acute Lung Injury in Mice.

Protective Effect of Edaravone on Ventilator Induced Lung Injury in Rats

Protective Effects of Edaravone on Renal Ischemia-Reperfusion Injury in Rats

Neuroprotective effect of edaravone on focal cerebral ischemia in rats

Edaravone alleviates lung damage in mice with hypoxic pulmonary hypertension by increasing nitric oxide synthase 3 expression

Therapeutic Effects of Edaravone on Acute Lung Injury in Rats

Protective effect of Edaravone on inhalation lung injury caused by black gunpowder smoke in rats

Targeting Reactive Oxygen Species by Edaravone Inhalation in A Rat Hyperoxic Lung Injury Model: Role of Inflammasome

Edaravone Attenuated Particulate Matter-Induced Lung Inflammation by Inhibiting ROS-NF-κB Signaling Pathway.

Protective effect of Edaravone on rat of pneumosilicosis

Edaravone combined with dexamethasone exhibits synergic effects on attenuating smoke-induced inhalation lung injury in rats

Edaravone attenuates cadmium-induced toxicity by inhibiting oxidative stress and inflammation in ICR mice

Edaravone attenuates lung injury in a hind limb ischemia-reperfusion rat model: A histological, immunohistochemical and biochemical study

Protective Effects of the Free Radical Scavenger Edaravone on Acute Pancreatitis-Associated Lung Injury.

Protective Role of Peroxisome Proliferator-Activated Receptor-Β/δ Against Pulmonary Oxygen Toxicity Mediated Through Changes in NOS Expression Levels

Edaravone protects HT22 neurons from H2O2-induced apoptosis by inhibiting the MAPK signaling pathway.

Edaravone Rescues the Lung by Inhibiting Lipid Peroxidation and Pro-Inflammatory Cytokines in a Rat Model.

Mechanisms of Protective Effects of Edaravone on Acute Lung Injury in Rats with Sepsis

Edaravone Protects PC12 Cells from Ischemic-Like Injury Via Attenuating the Damage to Mitochondria

Edaravone Protects Against Oxygen-Glucose-Serum Deprivation/Restoration-Induced Apoptosis in Spinal Cord Astrocytes by Inhibiting Integrated Stress Response